Sponsors
The bill provides dedicated financial relief, tax and benefit protections, and a specialized program for thalidomide survivors, but it limits who qualifies, leaves potential gaps in adequacy and funding reliability, and creates new administrative and fiscal costs for taxpayers and governments.
Thalidomide survivors who file approved petitions will receive direct financial relief (a one-time $150,000 payment and authorization for additional payments), providing immediate help with medical and living costs.
Recipients’ compensation will be excluded from means‑tested benefit calculations and from federal taxable income, so survivors keep access to programs like Medicaid/SNAP and receive higher after‑tax payments with less tax reporting burden.
The bill creates a dedicated compensation program with an expert review panel and authorized funding (FY2028–2034), establishing a formal, specialized process to evaluate claims and administer payments.
All taxpayers may face higher federal costs and modestly lower federal revenues because of new compensation payments, recurring appropriations, and the exclusion of those payments from taxable income.
Some eligible people could be excluded: only U.S. citizens or lawful permanent residents at exposure and filing qualify, and the bill imposes a single‑petition cap and a May 31, 2034 filing deadline that may bar late filers or those needing multiple claims.
The fixed $150,000 payment (and any additional payments dependent on annual appropriations) may be inadequate for survivors with severe, ongoing needs and risks inconsistent or insufficient support if Congress does not appropriate funds reliably.
Based on analysis of 7 sections of legislative text.
Creates a federal program to pay $150,000 to eligible U.S. thalidomide survivors, exempts payments from tax and means-tested benefit calculations, and requires annual HHS review and reporting.
Introduced October 28, 2025 by Jefferson Van Drew · Last progress October 28, 2025
Creates a federal compensation program to pay eligible U.S. survivors of in utero thalidomide exposure a one-time $150,000 payment, excludes those payments from federal income and from means-tested benefit calculations, and requires HHS to run, review, and report on the program. The bill limits applications to U.S. citizens or lawful permanent residents who were exposed and alive at filing, requires physician documentation and an expert-panel review, and sets a deadline for petitions and annual program reviews with possible additional payments subject to appropriations.